Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers
Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate approved by the FDA in 2013 for advanced HER2-positive breast cancer treatment exhibiting promising clinical benefits. However, HER2 overexpression and gene amplification have also been reported in other cancers like gastric cancer, non...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2023-05-01
|
| シリーズ: | Frontiers in Molecular Biosciences |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fmolb.2023.1165781/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|